Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Hoepner

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Cancer Immunology, Immunotherapy : CII|April 5, 2023
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patientsBerna C Özdemir, Cristina Espinosa da Silva, Dimitri Arangalage, et al.
Cancer Immunology, Immunotherapy : CII|May 8, 2023
Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patientsBerna C Özdemir, Cristina Espinosa da Silva, Dimitri Arangalage, et al.
Acta Neuropathologica|April 29, 2019
Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosisRobert Hoepner, Maud Bagnoud, Maximilian Pistor, et al.
Communications Biology|April 8, 2024
Klebsiella pneumoniae peptide hijacks a Streptococcus pneumoniae permease to subvert pneumococcal growth and colonizationJanine Lux, Hannah Portmann, Lucía Sánchez García, et al.
JMIR Medical Informatics|October 17, 2022
The Real-World Experiences of Persons With Multiple Sclerosis During the First COVID-19 Lockdown: Application of Natural Language ProcessingDeborah Chiavi, Christina Haag, Andrew Chan, et al.
The Lancet. Rheumatology|September 13, 2021
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label studyMatthias B Moor, Franziska Suter-Riniker, Michael P Horn, et al.
Annals of Neurology|April 15, 2014
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathyClemens Warnke, Gloria von Geldern, Philipp Markwerth, et al.
Brain, Behavior, and Immunity|July 6, 2026
Temelimab versus placebo in patients with post-COVID conditionMayssam Nehme, Margret Hund-Georgiadis, Esther Del Corral Beamonte, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2025
Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activitySofia Sandgren, Aleksandra Maleska Maceski, Pascal Benkert, et al.
European Journal of Neurology|December 17, 2024
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcomeGabriel Bsteh, Robert Hoepner, Jonathan A Gernert, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Cancer Immunology, Immunotherapy : CII|April 5, 2023
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patientsBerna C Özdemir, Cristina Espinosa da Silva, Dimitri Arangalage, et al.
Cancer Immunology, Immunotherapy : CII|May 8, 2023
Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patientsBerna C Özdemir, Cristina Espinosa da Silva, Dimitri Arangalage, et al.
Acta Neuropathologica|April 29, 2019
Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosisRobert Hoepner, Maud Bagnoud, Maximilian Pistor, et al.
Communications Biology|April 8, 2024
Klebsiella pneumoniae peptide hijacks a Streptococcus pneumoniae permease to subvert pneumococcal growth and colonizationJanine Lux, Hannah Portmann, Lucía Sánchez García, et al.
JMIR Medical Informatics|October 17, 2022
The Real-World Experiences of Persons With Multiple Sclerosis During the First COVID-19 Lockdown: Application of Natural Language ProcessingDeborah Chiavi, Christina Haag, Andrew Chan, et al.
The Lancet. Rheumatology|September 13, 2021
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label studyMatthias B Moor, Franziska Suter-Riniker, Michael P Horn, et al.
Annals of Neurology|April 15, 2014
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathyClemens Warnke, Gloria von Geldern, Philipp Markwerth, et al.
Brain, Behavior, and Immunity|July 6, 2026
Temelimab versus placebo in patients with post-COVID conditionMayssam Nehme, Margret Hund-Georgiadis, Esther Del Corral Beamonte, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2025
Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activitySofia Sandgren, Aleksandra Maleska Maceski, Pascal Benkert, et al.
European Journal of Neurology|December 17, 2024
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcomeGabriel Bsteh, Robert Hoepner, Jonathan A Gernert, et al.
Pageof 13